Transcatheter Market Research Report – Forecast to 2027

Transcatheter Market Research Report: By Type of Treatment (Transfemoral Approach, Transapical Approach, and Others), by Product Type (TAVR and TMVR), by End-User (Hospitals, Ambulatory Surgical Centers, Others), and by Region-Forecast Till 2027

ID: MRFR/MED/4757-CR | July 2018 | Region: Global | 100 pages

Transcatheter Market Overview:
The transcatheter market is expected to grow from USD 3,882.77 Mn in 2017 to more than USD 8,190 Mn by 2023-end.


Due to following a hectic lifestyle, the occurrence and recurrence of cardiovascular ailments have amplified throughout the whole world. Additionally, the commonality of hypertension, which is considered to be the prime cause of congestive heart failure and cardiac arrest, has been increasing as well.   

Thus, to treat these potentially life-threatening health conditions, the demand for minimally-invasive treatment options is growing as well. According to the experts, this massive demand for the same will prompt the colossal growth of the global Transcatheter Market during the projected forecast period.


COVID-19 Analysis of Transcatheter Market:
The unforeseen emergence of the COVID-19 pandemic has imposed negatively on the Transcatheter market, especially during the initial stage of the lockdown. Thus, the substantial growth of the same was thwarted for a specific period. Additionally, the resurgence of the endemic had also affected the availability of cardiac surgeons to some extent in the wake of pandemic-based restrictions. It, sequentially, affected the market growth as well. Nevertheless, during the latter half of 2020, the market for medical equipment began intensifying again owing to the distinctive symptoms of COVID-19. Due to the lack of awareness, many COVID-19 patients did not get treated within the initial stage.


It, successively, prompted the disease to infiltrate through the heart and cause cardiovascular complications. As a result, the reliance on the Transcatheter increased even more. Apparently, the sudden growth of dependence instinctively resulted in a rapid expansion of the Transcatheter Market as well. Furthermore, there is also a slight change that has been evident in the health equipment market. The manufacturers of the same are pouncing on the same and creating strategic moves to assimilate a remedial step in their offerings. According to experts, it might drive the growth of the market even further in the near future as well.


Transcatheter Market Dynamics:
Major Drivers of the Transcatheter Market
The prominence in the prevalence of mitral valve disorder and other major cardiovascular diseases has been amplifying since the last decade. As per the lifestyle experts, the commonness of the same will increase even more during the upcoming years due to lifestyle-related problems. The Transcatheter module, in essence, is primarily used for treating heart-related conditions. Hence, the ever-rising number of cardiovascular can be considered as the major driving factor in the uprising of the Transcatheter aortic valve replacement market size.



  • Opportunities


Previously, the growth of the transcatheter market size for Transcatheter aortic valve was more prominent in western countries. However, due to its overall efficiency regarding aortic valve treatment, more and more countries throughout the world are attempting to implement it. It, sequentially, can give a substantial boost to the market growth and prompt it to expand in a desirable manner. Furthermore, integrating various changes (such as equipment or medication) in the same can improve the effectiveness of the medical approach and increase its demand among patients.



  • Restraints


The Transcatheter aortic valve replacement is, in essence, a minimally-invasive medical procedure, which is used to replace the aortic valve of the patient. It is done so without the removal of the damaged or older valve. The whole modus operandi of the medical procedure is already quite well-developed and –designed. However, there are still some issues regarding the same available, which can restrain the growth of the Transcatheter aortic valve implantation market. Amongst them, the difficulty of the procedure is considered to be quite prevalent. The medical process, in essence, is quite intricate and, therefore, is prone to failure. Thus, many patients tend to choose the safer options in this aspect. Furthermore, there is no surety that the procedure can be effective for the individual for over ten years. It is yet another aspect, which might prevent an individual to avoid it.



  • Challenges


The occurrence of the calamitous COVID-19 pandemic had imposed an abrupt halt in the growth of the Transcatheter Market. So, it can continue to be a threat of the same during the later years as well. Furthermore, the overall cost of the procedure is quite high as well. It can also prompt the patients, who belong to the middle-class segment, to avoid the same. This specific challenge can pose to affect the transcatheter market for a prolonged period.



  • Cumulative Growth Analysis


The approximate growth percentage of the Transcatheter aortic valve implantation market has been recorded at 14.4%. The expansion of the same will excel even more during the latter years and reach the market of $4.67 billion by the year of 2027. The values provided here are based on the current and rising demand for the procedure. It might increase or decrease depending on the strata of the market in the near future. However, the end result will not be much different from the provided expectation at all.


Value Chain Analysis of Transcatheter Market:
Having thorough know-how about the value chain of the Transcatheter heart valve market is imperative to perceive its growth potential. The uprising in the worth of the aforementioned market primarily depends on the usage of technology during the procedure. In the upcoming years, the development and prominence of the same will improve exponentially. Thus, the value of the transcatheter market is also anticipated to increase massively alongside the same.


Transcatheter Market Segment Overview:
The global Transcatheter Market can be segmented by the type of treatment procedure and the end-user.



  • By Type


By the type of treatment, the Transcatheter heart valve market is segmented into the transapical approach, transaortic approach, and transfemoral approach. Amongst these, the transfemoral approach is anticipated to lead the market during the forecast period due to the sudden increase in the prominence of valvular diseases.


The vulnerability to cardiovascular ailments among the geriatric population can prompt its growth as well. Conversely, the transaortic segment will predictably depict a stern CAGR rating owing to the frequent usage of the aorta cannulation procedure during ongoing cardiac surgeries.



  • By End-User


The end-users in the Transcatheter heart valve replacement market include – the ambulatory surgical center, cardiac catheterization laboratory, and hospital. Amidst them, the hospitals are considered to be the largest end-user of the Transcatheter procedure.


Thus, it will bring in the highest amount of revenue as well. The reasons for such a massive growth can be credited to the patient volume, the profusion of equipment and skilled surgeon, and various insurance schemes covering up the medical procedures.


Transcatheter Market Regional Analysis:
North America to Grow Exponentially During the Forecast Period:
The regional segment for the global Transcatheter Market can be categorized into – North America, South America, Asia, Europe, and Middle East & Africa. Amongst them, North America currently holds the largest share of the market owing to the contributions of Canada and the USA. The utter prevalence of the well-established medical sector along with the prevalence of cardiovascular disease will prompt growth in this region. Aside from NA, Europe will experience the same amount of growth due to similar reasons like the USA.


Transcatheter Market Competitive Landscape:
The Meril Life Sciences PVT. LTD is considered to be one of the key players in the competitive landscape of the Transcatheter market. The organization is primarily known for its innovativeness while creating the necessary equipment regarding the procedure.


The Boston Scientific Corporation is one of the major manufacturers of the implanted devices and coronary stents. They tend to operate through a more direct marketing procedure and create simplified devices to hold the leading position firmly.


The list of key companies covered in the report is -



  • Edwards Lifesciences Corporation

  • JenaValve Technology, Inc

  • Terumo Corporation

  • Neovasc Inc.

  • Edwards Lifesciences Corporation


Transcatheter Market Recent Developments:



  • The MitraClip has become the first and the only FDA-cleared device in the current scenario.

  • The Transcatheter Mitral Valves are working towards a proper market clearance.

  • In 2018, Abbott initiated a clinical summit on the Treatment of Symptomatic Mitral Regurgitation.

  • In 2017, Medtronic renounced the implantation of the Intrepid TMVR System on the first patient in the world.


Transcatheter Market Report Overview


The report overview of the same is as follows –



  • Overview of the market

  • COVID 19 analysis

  • Dynamics of the market

  • Value chain analysis

  • Market segmentation

  • Regional analysis

  • Competitive analysis

  • Recent Developments of the key players


The scope of the report is to provide clarity on the subject of the Transcatheter market’s potential growth and highlights its overall strengths. Moreover, it also aims to provide a subtle amount of information on the key players of the transcatheter market .


Transcatheter Market Segmentation Table”


By Type



  • Transapical approach

  • Transaortic approach

  • transfemoral approach


By End-User



  • Ambulatory surgical center

  • Cardiac catheterization laboratory

  • Hospital


By Region



  • North America


    • US

    • Canada


  • Europe


    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe


  • Asia-Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • Rest of the World


    • Middle East

    • Africa

    • Latin America




Report Scope:
Report Attribute/Metric Details
  Market Size   2023: USD 8,190 Mn
  CAGR   2018-2023: Substantial CAGR
  Base Year   2019
  Forecast Period   20227
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type Of Treatment Procedure and The End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Edwards Lifesciences Corporation, JenaValve Technology, Inc, Terumo Corporation, Neovasc Inc., Edwards Lifesciences Corporation
  Key Market Opportunities   Efficiency Regarding Aortic Valve Treatment
  Key Market Drivers   the massive prevalence of chronic cardiovascular disease, minimally invasive medical procedures, and the ever-growing preference for the Transcatheter process.


Frequently Asked Questions (FAQ) :


The North American region will grow the most during this period. However, a similar form of growth can be seen for the European continent as well.

Transcatheter market would reach up to a valuation of USD 8190 million.

Transcatheter market would attain a CAGR of 13.38% during the forecast period of 2020 to 2027.

The TAVR segment has control of the transcatheter market.

The transcatheter market includes segments like hospitals, ambulatory surgical centers (ASCs), and cardiac catheterization laboratory.

The Transcatheter Market will grow at a CAGR of 14.4% by 2027.

The prime driving factors of the market are – the massive prevalence of chronic cardiovascular disease, minimally invasive medical procedures, and the ever-growing preference for the Transcatheter process.

The transcatheter market is expected to grow at an above average CAGR of 13.38% during the forecast period. Incidences of cardiovascular diseases have been growing globally due to changes in diet and the prevalence of a sedentary lifestyle; this among other factors is expected to contribute to market growth over the next five years. Valued at USD 3.88 billion in 2017, the global transcatheter market is poised to reach an approximate evaluation of USD 8.19 billion by the end of 2023.


The increasing prevalence of cardiovascular diseases and the associated morbidity rate has garnered a lot of attention from the healthcare sector. Leading market players are competing fiercely in an effort to introduce effective treatment options in the market. Transcatheters are commonly used to treat aortic valve diseases such as Aortic Valve Stenosis (AS) which is the most frequently occurring valve disease leading to surgical or transcatheter valve replacement in North America and Europe. Many patients with cardiovascular diseases usually have to undergo surgical procedures to treat the problem effectively, and preferences lean toward minimally invasive procedures. The minimally invasive surgical procedure repairs the valve without removing the old, damaged valve. Instead, it wedges a replacement valve at the place of the aortic valve. The surgical procedure is also known as Transcatheter Aortic Valve Replacement (TAVR) or Transcatheter Aortic Valve Implantation (TAVI). The increasing demand for advanced and minimally invasive procedures combined with the growing geriatric populations who display a high susceptibility to cardiovascular diseases is expected to drive demand for transcatheters during the forecast period.


Since some cardiovascular devices, including transcatheters, are in direct contact with the body in the process of treatment, there is an increased risk of infection which has prompted the standardization of the product. A strict regulatory framework is expected to show market growth and restraining growth at a minimal CAGR of -0.6% during the assessment period. Ongoing advancements in the development of novel catheter devices for cardiac problems is expected to lead the market toward opportunities for future growth in the next few years.


The global transcatheter market is segmented on the basis of type of treatment, product type, end-user, and region. By type of treatment, the market is segmented into transfemoral approach, transapical approach, and transaortic approach, and transaortic approach. The transfemoral approach presently holds the leading position in the market due to the increased incidences of valvular heart diseases in the increasing. Geriatric population. Meanwhile, the transaortic segment is expected to achieve the highest CAGR during the forecast period due to the increasingly routine aorta cannulation procedure in cardiac surgeries.


By product type, the market is segmented into transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR). The TAVR segment has the largest share of the total market due to the advancements in the product and the high adoption of TAVR over TMVR. TAVR involves repairing of the valve without removal of the old, damaged valve.


By end-user, the market is segmented into hospitals, ambulatory surgical centers (ASCs), and cardiac catheterization laboratory. The hospital segment accounts for the largest segment. Hospitals are the biggest end-users in the market due to the high number of patients with cardiac problems that go to hospitals for various treatment procedures and health check-ups. Hospitals are often where cardiac problems are diagnosed, and treated.


Regional Analysis


Led by countries such as the U.S. and Canada, the Americas possess the largest share of the global transcatheter market. The presence of market-leading players who are investing in the technological advancement of the product and the presence of a well-developed healthcare sector with favorable reimbursement policies are key drivers of growth for the region. Europe closely follows Americas’ lead and has a similar growth pattern. The region has a high geriatric population and increasing diagnoses of endovascular diseases where transcatheters are vital in treatment; this is expected to boost demand in the region and reflect market growth for the region in the global market.


The Asia-Pacific is the fastest growing region in the global market due to the gradual transformation of the region, economically and otherwise. The adoption of western trends in the region, growing urbanization, and the change in lifestyle habits have led to an increase in cardiovascular diseases. Densely populated emerging economies in the region such as India and China are driving growth for the market as there is a large population base, a significant share of which is geriatric. The improving infrastructure and development of the healthcare sector are expected to increase demand for advanced products. Growing awareness of healthcare procedures and diseases has led to high demand for advanced medical devices in the region, thus translating to growth for the transcatheter market.


Competitive Tracking


Top players in the global market, on the basis of the market study, have been identified and included in the report. Prominent players leading the market include Edwards Lifesciences Corporation, Boston Scientific Corporation, Medtronic plc, and Abbot Laboratories Inc. Other important players include JenaValve Technology Inc., Meril Life Sciences Pvt. Ltd., and Braile Biomedica among others.

1 Executive Summary

2 Market Introduction

2.1 Scope Of The Study 16

2.2 Research Objective 16

2.3 List Of Assumptions 16

2.4 Market Structure 17

3 Research Methodology

3.1 Research Process 19

3.2 Primary Research 20

3.3 Secondary Research 21

3.4 Market Size Estimation 22

3.5 Forecast Model 22

4 Market Dynamics

4.1 Drivers 24

4.1.1 Introduction 24

4.1.2 Increase In Preference For Minimally Invasive Procedures 25

4.1.3 Increasing Prevalence Of Cardiovascular Diseases 26

4.1.4 Favorable Reimbursement Policies 27

4.2 Restraints 28

4.2.1 Strict Regulatory Guidelines 28

4.2.2 Risk Of Infection 28

4.3 Opportunities 29

4.3.1 New Advancements In Novel Cardiac Catheterization Devices 29

5 Market Factor Analysis

5.1 Value Chain Analysis 31

5.1.1 R&D And Designing 31

5.1.2 Manufacturing 31

5.1.3 Distribution & Sales 31

5.1.4 Post-Sales Monitoring 32

5.2 Porter’s Five Forces Model 32

5.2.1 Bargaining Power Of Suppliers 32

5.2.2 Bargaining Power Of Buyers 33

5.2.3 Threat Of New Entrants 33

5.2.4 Threat Of Substitutes 33

5.2.5 Intensity Of Rivalry 33

5.3 Demand & Supply: Gap Analysis 34

5.4 Pricing Analysis 34

6 Transcatheter Market, By Type Of Treatment

6.1 Overview 36

6.1.1 Transfemoral Approach 37

6.1.2 Transapical Approach 37

6.1.3 Transaortic Approach 38

7 Transcatheter Market, By Product Type

7.1 Introduction 40

7.1.1 Transcatheter Aortic Valve Replacement (TAVR) 41

7.1.2 Transcatheter Mitral Valve Repair (TMVR) 41

8 Transcatheter Market, By End User

8.1 Introduction 43

8.1.1 Hospitals 44

8.1.2 Ambulatory Surgical Centres (ASCs) 44

8.1.3 Cardiac Catheterization Laboratory 44

9 Global Transcatheter Market, By Region

9.1 Introduction 46

9.2 Americas 47

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.2.1 North America 48

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.2.1.1 U.S. 49

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.2.1.2 Canada 50

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.2.2 South America 51

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.3 Europe 53

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.3.1 Germany 55

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.3.2 U.K 56

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.3.3 France 57

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.3.4 Spain 58

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.3.5 Italy 59

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.3.6 Rest Of Europe 60

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.4 Asia Pacific 61

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.4.1 China 63

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.4.2 Japan 64

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.4.3 India 65

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.4.4 Australia 66

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.4.5 Rest Of Asia Pacific 67

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.5 Middle East & Africa 68

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.5.1 Middle East 70

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

9.5.2 Africa 71

Transcatheter Market, By Type Of Treatment

Transcatheter Market, By Product Type

Transcatheter Market, By End User

10 Company Landscape

10.1 Company Market Share Analysis 73

10.1.1 Introduction 73

10.2 Competitive Landscape 74

10.2.1 Introduction 74

10.3 Key Developments 75

11 Company Profiles

11.1 Edwards Lifesciences Corporation 78

11.1.1 Company Overview 78

11.1.2 Financial Overview 78

11.1.3 Products Offering 79

11.1.4 Key Developments 79

11.1.5 SWOT Analysis 79

11.1.6 1.1.6 Key Strategy 79

11.2 Meril Life Sciences Pvt. Ltd. 80

11.2.1 1.2.1 Company Overview 80

11.2.2 Financial Overview 80

11.2.3 Products Offering 80

11.2.4 Key Developments 80

11.2.5 1.2.5 SWOT Analysis 80

11.2.6 Key Strategy 80

11.3 Braile Biomedica 81

11.3.1 1.3.1 Company Overview 81

11.3.2 Financial Overview 81

11.3.3 Products Offering 81

11.3.4 Key Developments 81

11.3.5 SWOT Analysis 81

11.3.6 Key Strategy 81

11.4 Venus Medtech 82

11.4.1 1.4.1 Company Overview 82

11.4.2 Financial Overview 82

11.4.3 Products Offering 82

11.4.4 Key Developments 82

11.4.5 Key Strategy 83

11.5 Boston Scientific Corporation 84

11.5.1 Company Overview 84

11.5.2 Financial Overview 84

11.5.3 Products Offering 85

11.5.4 Key Developments 85

11.5.5 Key Strategy 85

11.6 JenaValve Technology, Inc. 86

11.6.1 Company Overview 86

11.6.2 Financial Overview 86

11.6.3 Products Offering 86

11.6.4 Key Developments 86

11.6.5 SWOT Analysis 87

11.6.6 Key Strategy 87

11.7 Abbott Laboratories 88

11.7.1 Company Overview 88

11.7.2 Financial Overview 88

11.7.3 Products Offering 89

11.7.4 Key Developments 89

11.7.5 SWOT Analysis 89

11.7.6 1.7.6 Key Strategy 89

11.8 Medtronic PLC 90

11.8.1 Company Overview 90

11.8.2 Financial Overview 90

11.8.3 Products Offering 91

11.8.4 Key Developments 91

11.8.5 SWOT Analysis 91

11.8.6 Key Strategy 91

11.9 Bracco Diagnostic Inc. 92

11.9.1 Company Overview 92

11.9.2 Financial Overview 92

11.9.3 Products Offering 92

11.9.4 Key Developments 92

11.9.5 SWOT Analysis 93

11.9.6 Key Strategy 93

11.10 Cook Medical Inc. 94

11.10.1 Company Overview 94

11.10.2 Financial Overview: 94

11.10.3 Products Offering 94

11.10.4 Key Developments 94

11.10.5 SWOT Analysis 95

11.10.6 Key Strategy 95

12 Appendix

12.1 Discussion Blue Print 97

12.2 Reference 99


13 List Of Tables

TABLE 1 MARKET SYNOPSIS 14

TABLE 2 LIST OF ASSUMPTIONS 16

TABLE 3 PRIMARY INTERVIEWS 19

TABLE 4 GLOBAL TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 36

TABLE 5 GLOBAL TRANSCATHETERSS MARKET FOR TRANSFEMORAL APPROACH, BY REGION 2020-2027 (USD MILLION) 37

TABLE 6 GLOBAL TRANSCATHETERSS MARKET FOR TRANSAPICAL APPROACH, BY REGION 2020-2027 (USD MILLION) 37

TABLE 7 GLOBAL TRANSCATHETERSS MARKET FOR TRANSAORTIC APPROACH, BY REGION 2020-2027 (USD MILLION) 38

TABLE 8 GLOBAL TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 40

TABLE 9 GLOBAL TRANSCATHETERSS MARKET FOR TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR), BY REGION 2020-2027 (USD MILLION) 41

TABLE 10 GLOBAL TRANSCATHETERSS MARKET FOR TRANSCATHETER MITRAL VALVE REPAIR (TMVR), BY REGION 2020-2027 (USD MILLION) 41

TABLE 11 GLOBAL TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 43

TABLE 12 GLOBAL TRANSCATHETERSS MARKET FOR HOSPITALS, BY REGION 2020-2027 (USD MILLION) 44

TABLE 13 GLOBAL TRANSCATHETERSS MARKET FOR AMBULATORY SURGICAL CENTERS (ASCS), BY REGION 2020-2027 (USD MILLION) 44

TABLE 14 GLOBAL TRANSCATHETERSS MARKET FOR CARDIAC CATHETERIZATION LABORATORY, BY REGION 2020-2027 (USD MILLION) 44

TABLE 15 GLOBAL TRANSCATHETER MARKET, BY REGION 2020-2027 (USD MILLION) 46

TABLE 16 AMERICAS TRANSCATHETER MARKET, BY REGION 2020-2027 (USD MILLION) 47

TABLE 17 NORTH AMERICA TRANSCATHETER MARKET, BY COUNTRY 2020-2027 (USD MILLION) 48

TABLE 18 NORTH AMERICA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 48

TABLE 19 NORTH AMERICA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 49

TABLE 20 NORTH AMERICA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 49

TABLE 21 U.S. TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 49

TABLE 22 U.S. TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 50

TABLE 23 U.S. TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 50

TABLE 24 CANADA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 50

TABLE 25 CANADA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 51

TABLE 26 CANADA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 51

TABLE 27 SOUTH AMERICA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 51

TABLE 28 SOUTH AMERICA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 52

TABLE 29 SOUTH AMERICA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 52

TABLE 30 EUROPE TRANSCATHETER MARKET, BY COUNTRY 2020-2027 (USD MILLION) 53

TABLE 31 EUROPE TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 54

TABLE 32 EUROPE TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 54

TABLE 33 EUROPE TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 54

TABLE 34 GERMANY TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 55

TABLE 35 GERMANY TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 55

TABLE 36 GERMANY TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 55

TABLE 37 U.K TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 56

TABLE 38 U.K TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 56

TABLE 39 U.K TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 56

TABLE 40 FRANCE TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 57

TABLE 41 FRANCE TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 57

TABLE 42 FRANCE TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 57

TABLE 43 SPAIN TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 58

TABLE 44 SPAIN TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 58

TABLE 45 SPAIN TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 58

TABLE 46 ITALY TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 59

TABLE 47 ITALY TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 59

TABLE 48 ITALY TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 59

TABLE 49 REST OF EUROPE TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 60

TABLE 50 REST OF EUROPE TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 60

TABLE 51 REST OF EUROPE TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 60

TABLE 52 ASIA PACFIC TRANSCATHETER MARKET, BY COUNTRY 2020-2027 (USD MILLION) 61

TABLE 53 ASIA PACIFIC TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 62

TABLE 54 ASIA PACIFIC TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 62

TABLE 55 ASIA PACIFIC TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 63

TABLE 56 CHINA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 63

TABLE 57 CHINA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 63

TABLE 58 CHINA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 64

TABLE 59 JAPAN TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 64

TABLE 60 JAPAN TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 64

TABLE 61 JAPAN TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 65

TABLE 62 INDIA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 65

TABLE 63 INDIA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 65

TABLE 64 INDIA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 66

TABLE 65 AUSTRALIA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 66

TABLE 66 AUSTRALIA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 66

TABLE 67 AUSTRALIA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 67

TABLE 68 REST OF ASIA PACIFIC TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 67

TABLE 69 REST OF ASIA PACIFIC TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 67

TABLE 70 REST OF ASIA PACIFIC TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 68

TABLE 71 MIDDLE EAST & AFRICA TRANSCATHETER MARKET, BY COUNTRY 2020-2027 (USD MILLION) 68

TABLE 72 MIDDLE EAST & AFRICA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 69

TABLE 73 MIDDLE EAST & AFRICA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 69

TABLE 74 MIDDLE EAST & AFRICA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 69

TABLE 75 MIDDLE EAST TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 70

TABLE 76 MIDDLE EAST TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 70

TABLE 77 MIDDLE EAST TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 70

TABLE 78 AFRICA TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020-2027 (USD MILLION) 71

TABLE 79 AFRICA TRANSCATHETER MARKET, BY PRODUCT TYPE 2020-2027 (USD MILLION) 71

TABLE 80 AFRICA TRANSCATHETER MARKET, BY END USER 2020-2027 (USD MILLION) 71

TABLE 81 GLOBAL TRANSCATHETERS MARKET: KEY DEVELOPMENT 75


14 List Of Figures

FIGURE 1 GLOBAL TRANSCATHETER MARKET: MARKET STRUCTURE 17

FIGURE 2 RESEARCH PROCESS 19

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 22

FIGURE 4 VALUE CHAIN: TRANSCATHETER MARKET 31

FIGURE 5 PORTERS FIVE FORCES MODEL 32

FIGURE 6 GLOBAL TRANSCATHETER MARKET, BY TYPE OF TREATMENT 2020 & 2027 (USD MILLION) 37

FIGURE 7 GLOBAL TRANSCATHETER MARKET, BY PRODUCT TYPE 2020 & 2027 (USD MILLION) 40

FIGURE 8 GLOBAL TRANSCATHETER MARKET, BY END USER 2020 & 2027 (USD MILLION) 43

FIGURE 9 GLOBAL TRANSCATHETER MARKET, BY REGION 2020 & 2027 (USD MILLION) 46

FIGURE 10 AMERICAS TRANSCATHETER MARKET, BY REGION 2020 (%) 47

FIGURE 11 NORTH AMERICA TRANSCATHETER MARKET, BY COUNTRY 2020 (%) 48

FIGURE 12 EUROPE TRANSCATHETER MARKET, BY COUNTRY 2020 (%) 53

FIGURE 13 ASIA PACFIC TRANSCATHETER MARKET, BY COUNTRY 2020 & 2027 (%) 62

FIGURE 14 MIDDLE EAST & AFRICA TRANSCATHETER MARKET, BY COUNTRY 2020 & 2027 (%) 69

FIGURE 15 GLOBAL TRANSCATHETERS MARKET, MARKET SHARE ANALYSIS 2020 (%) 73

FIGURE 16 GLOBAL TRANSCATHETERS MARKET COMPETITIVE LANDSCAPE (%) 74

 Global Transcatheter Market: Competitive Landscape


Edwards Lifesciences Corporation, Medtronic plc., Boston Scientific Corporation, and Abbott Laboratories Inc. accounted for approximately 52% share of the global transcatheter market in 2017. These companies continue to retain their strong global presence through expansions, mergers and acquisitions, and extensive product portfolio.


Edwards Lifesciences Corporation is an American company known for manufacturing heart valve systems and repair products. The company’s transcatheter heart valve therapy and surgical heart valve therapy products are manufactured in the US, Singapore, and Switzerland. The company’s subsidiaries include Edwards Lifesciences Asset Management Corporation, Edwards Lifesciences CardiAQ LLC., Valtech Cardio Inc., and Red Hill Insurance Corporation.


Medtronic plc accounted for the second largest market share of the global transcatheter market owing to the innovation of less-invasive, miniaturized, and Mechanical Circulatory Support (MCS) technologies for treating patients with advanced heart failure. The company has the ability to create meaningful innovations for hospitals, health systems, and healthcare providers and the ability to deliver the best care possible to patients around the world.


Boston Scientific Corporation is the developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties. The company held the third position in terms of market share in 2017. It is dedicated to collaborating with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, increase efficiencies, and most importantly, help people around the world to live longer and healthier. Boston Scientific offers a wide range of products categorized as featured products, medical specialty, and many others.


Medtronic, Inc. manufactures and sells device-based medical therapies. The company manufactures image-guided surgery and intra-operative imaging systems. Its products include electrophysiology catheters implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain and other disorders.


Abbott Laboratories Inc. has a significant product portfolio which focuses on discovery, development, manufacturing, and sales of healthcare products. The company operates through four reportable segments, namely, established pharmaceutical products, diagnostic products, nutritional products, and vascular products. Furthermore, the company has two non-reportable segments, namely, diabetes care and medical optics. The diabetes care division of the company is located in California, US and provides blood glucose meters, blood glucose test strips, sensors, data management decision software, and accessories. The company manufactures its blood glucose test strips at Witney, UK site.


The global transcatheter market is a promptly growing market and involves the manufacturing of various types of transcatheter for different cardiovascular procedures. Hence, the market is not completely dominated by any one or two players but is fairly divided among the top transcatheter’ manufacturing companies. Many leading players are focusing on the American and European markets owing to well-established markets, huge patient population, and high healthcare expenditures. These players have expanded their market in other regions as well. Major companies have a huge brand identity and product portfolio. These companies have adopted the organic strategy of product launches and acquisitions to gain the market.